Cellebrite DI (NASDAQ:CLBT) CRO Marcus Jewell Sells 12,658 Shares of Stock

Cellebrite DI Ltd. (NASDAQ:CLBT) CRO Marcus Jewell sold 12,658 shares of the firm’s stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $12.77, for a total value of $161,642.66. Following the completion of the sale, the executive directly owned 440,101 shares of the company’s stock, valued at $5,620,089.77. This represents a 2.80% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Marcus Jewell also recently made the following trade(s):

• On Tuesday, May 12th, Marcus Jewell sold 383 shares of Cellebrite DI stock. The shares were sold at an average price of $13.01, for a total value of $4,982.83.

Cellebrite DI Price Performance

CLBT opened at $13.46 on Wednesday. The business has a 50 day simple moving average of $13.47 and a 200-day simple moving average of $15.45. The stock has a market capitalization of $3.36 billion, a P/E ratio of 48.07, a P/E/G ratio of 1.63 and a beta of 1.15. Cellebrite DI Ltd. has a 12 month low of $11.02 and a 12 month high of $19.98.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Wealth Enhancement Advisory Services LLC increased its holdings in Cellebrite DI by 40.4% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 359,764 shares of the company’s stock valued at $6,652,000 after buying an additional 103,568 shares during the last quarter. Norwood Investment Partners LP bought a new position in shares of Cellebrite DI during the third quarter valued at approximately $4,274,000. TimesSquare Capital Management LLC bought a new position in shares of Cellebrite DI during the third quarter valued at approximately $11,217,000. Migdal Insurance & Financial Holdings Ltd. bought a new position in shares of Cellebrite DI during the third quarter valued at approximately $19,457,000. Finally, Wisconsin Capital Management LLC bought a new position in Cellebrite DI in the 3rd quarter worth approximately $1,649,000. Institutional investors and hedge funds own 45.88% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on CLBT shares. Needham & Company LLC dropped their price objective on Cellebrite DI from $18.00 to $15.00 and set a “buy” rating for the company in a research note on Friday, May 15th. Weiss Ratings upgraded Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday. Finally, Wall Street Zen upgraded Cellebrite DI from a “sell” rating to a “hold” rating in a report on Sunday, March 15th. Four research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $21.75.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.